SCHEMBL10134816

SCHEMBL10134816

O=C(Nc1ccccc1)c1cncc(Nc2ccncc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.53
TYK2 P29597 2/20 0.53
HTT P42858 1/20 0.53
TAAR1 Q96RJ0 1/20 0.51
CDK2 P24941 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.50
GRM5 P41594 2/20 0.49
CNR1 P21554 2/20 0.48
STAT3 P40763 1/20 0.48
KMT2A Q03164 2/20 0.47
NT5E P21589 1/20 0.47
BRAF P15056 1/20 0.46
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46
GSK3A P49840 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134797 0.94 CDK2 (0.57) HTTCDK2SMN1; SMN2POLBGRM5
SCHEMBL10134810 0.88 RAB9A (0.56) SMN1; SMN2POLBGRM5KMT2AKDM4E
SCHEMBL10134808 0.82 NPC1 (0.51) HTTSMN1; SMN2POLBKMT2ABRAF
SCHEMBL10366486 0.80 CDK2 (0.45) JAK2TYK2CDK2SMN1; SMN2POLB
SCHEMBL10134802 0.77 KMT2A (0.54) HTTCDK2SMN1; SMN2STAT3KMT2A
SCHEMBL560267 0.76 ATR (0.68)
SCHEMBL7861675 0.75 GRM5 (0.65) SMN1; SMN2POLBGRM5CNR1KDM4E
SCHEMBL10134799 0.74 NPC1 (0.48) JAK2CNR1RAB9ANPC1GSK3B
SCHEMBL14308717 0.73 CDK2 (0.74) CDK2KMT2ABRAFKDM4ERAB9A
SCHEMBL16420803 0.72 IRAK4 (0.63) CNR1KMT2ARAB9ANPC1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 JAK2 342/4885TYK2 412/4885HTT 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.